ClinicalTrials.gg
CompletedNCT01055444Updated Mar 16, 2012

Study Evaluating Heated Lidocaine/Tetracaine Topical Patch in Treatment of Patients With Shoulder Impingement Syndrome

A Phase 2 interventional study of Heated lidocaine and tetracaine topical patch in Shoulder Impingement Syndrome, sponsored by ZARS Pharma Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-03-16.

Sponsored by ZARS Pharma Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies in Shoulder Impingement Syndrome with a site in United States — 3 open to participants now, 4 under way, none of them phase 3. Shoulder Impingement Syndrome · United States.

Enrollment
22nd of 27
20 · median 40
Started
2010
with 2 others
Phase 2
4 of 31
none open now
Registered
4th of 31
by date

Among the 31 studies in Shoulder Impingement Syndrome with a site in United States, this one is the 22nd largest by enrollment of the 27 interventional ones that give a count, is one of 3 that started in 2010, is one of 4 in phase 2, and was the 4th registered.

Shoulder Impingement Syndrome

320 studies on the registry are indexed under Shoulder Impingement Syndrome; 62 are open to participants now.

Browse Shoulder Impingement Syndrome studies →

Open to participants now

3 of the 31 studies in Shoulder Impingement Syndrome with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 32 Shoulder Impingement Syndrome studies recruiting now, 3 (9%) set no upper age limit and 25 (78%) stop at 75 or younger; 1 takes children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Shoulder Impingement Syndrome with a site in United States, or all of them as a file.
02

Study summary

The purpose of the study is to explore the potential usefulness of a heated lidocaine 70 mg/tetracaine 70 mg topical patch for the treatment of pain associated with shoulder impingement syndrome

Read the detailed description

The purpose of this single center, 2-week open-label pilot study is to explore the potential usefulness of a heated lidocaine 70 mg and tetracaine 70 mg topical patch for the treatment of pain associated with shoulder impingement syndrome. A number of efficacy variables will be employed to evaluate their utility for assessing painful responses in this population.

03

Conditions studied

  • Shoulder Impingement Syndrome
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pain associated with shoulder impingement syndrome in a single shoulder
  • Have tenderness at the attachment site of the rotator cuff tendons in the affected shoulder
  • Have positive Hawkins and Neers signs

Exclusion criteria

Exclusion Criteria:

  • Have used any topically applied pain medication on the target treatment area within 3 days preceding the Screening/Baseline visit
  • Have used any injected pain medication within 14 days preceding the Screening/Baseline visit
  • Are receiving class 1 antiarrhythmic drugs (ie, tocainide, mexiletine, etc.)
  • Have a history of and/or past diagnosis of severe hepatic disease

Other protocol-defined inclusion/exclusion criteria may apply

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Heated lidocaine/tetracaine topical patch

    Patients will be instructed to apply one heated lidocaine 70 mg and tetracaine 70 mg topical patch to the affected shoulder every 12 hours starting on the evening of Day 1 through the morning of Day 14 (morning and evening applications) and to remove the patch after 2-4 hours.

    Drug: Heated lidocaine and tetracaine topical patch

Interventions

  • DrugHeated lidocaine and tetracaine topical patch

    Drug page: Lidocaine

    Patients will be instructed to apply one heated lidocaine 70 mg and tetracaine 70 mg topical patch to the affected shoulder every 12 hours starting on the evening of Day 1 through the morning of Day 14 (morning and evening applications) and to remove the patch after 2-4 hours.

    Also known as: Synera

06

What researchers measure

Primary outcomes

  1. Pain intensity

    Time frame: Two weeks

Secondary outcomes

  1. Pain interference with activities (general, normal work, and sleep)

    Time frame: Two weeks

07

Study locations

1 site
  • Injury Care Medical Center
    Boise, Idaho 83713, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2010, a primary completion of Aug 2010 and a completion of Sep 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 21, 2010
First posted
Jan 25, 2010
Start
Mar 2010
Primary completionActual
Aug 2010
CompletionActual
Sep 2010
Results delay requested
Mar 14, 2012
Last update
Mar 16, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 16, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01055444
Lead sponsor
ZARS Pharma Inc.
Responsible party
Sponsor
First posted
Jan 25, 2010
Start date
Mar 2010
Primary completion
Aug 2010
Completion
Sep 2010
Last update
Mar 16, 2012

Study contacts

Richard Radnovich, DO
principal investigator

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lidocaine

Start the discussion